Articles tagged "Immunosuppression"

2022 American Transplant Congress
Evaluation of Conversion from Immediate Release (IR) Tacrolimus to LCP-Tacrolimus (Envarsus XR®, LCP) in Heart Transplant Recipients
E. Foster¹, A. Iaria¹, J. Negrelli², M. Fine², M. Yu², M. Liebo²
¹University of Illinois at Chicago, Chicago, IL, ²Loyola University Medical Center, Maywood, IL
*Purpose: The purpose of this study was to assess outcomes in heart transplant recipients who were converted from IR tacrolimus to LCPT. Limited data exists…
2022 American Transplant Congress
Variation in Immunosuppressive Regimen in Children Receiving Liver Transplants: An Analysis of the UNOS Database
V. K. Raghu¹, J. E. Squires¹, C. Confair², E. Katz-Eisenberg², G. V. Mazariegos³, E. R. Perito⁴
¹Pediatrics, University of Pittsburgh, Pittsburgh, PA, ²Starzl Network for Excellence in Pediatric Transplantation, Pittsburgh, PA, ³UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, ⁴Pediatrics, University of California San Francisco, San Francisco, CA
*Purpose: Optimizing immunosuppression (IS) was identified as a priority for pediatric liver transplant (LT) families and providers in the Starzl Network, a multi-center learning health…
2022 American Transplant Congress
Pediatric Liver Transplant Factors That Influence Tacrolimus Absorption
M. Chandran¹, D. Yoeli¹, A. Sater², F. Karrer¹, M. Adams¹
¹Children's Hospital Colorado, Aurora, CO, ²University of Colorado, Aurora, CO
*Purpose: The aim of this study was to investigate the association between various pediatric recipient characteristics at time of liver transplant and FK506 absorption 6…
2022 American Transplant Congress
Impact of Respiratory Viral Panel Testing on Clinical Decision-Making Among Lung Transplant Recipients Based on Extent of Immunosuppression
A. C. Vostal¹, A. Lynen², S. Chintalapati¹, M. Uehling¹, K. Prakash², A. Shishido¹, J. Baghdadi²
¹University of Maryland Medical Center, Baltimore, MD, ²University of Maryland School of Medicine, Baltimore, MD
*Purpose: Lung transplant recipients (LTRs) are at high risk for complications from viral respiratory infection, including chronic allograft dysfunction. Thus, multiplex molecular testing for respiratory…
2022 American Transplant Congress
Longitudinal Characterization of the Microvirome in a Cohort of Renal Transplant Recipients
A. C. Johnson, G. Karadkhele, C. P. Larsen
Emory University, Atlanta, GA
*Purpose: The selective targeting of T cells in transplant immunosuppression medications leads to a high rate of viral infections, with different immunosuppression regimens resulting in…
2022 American Transplant Congress
Humoral and Cellular Immunity 6 Months After SARS-CoV-2 Infection in Solid-Organ Transplant Recipients
S. Morris¹, S. Courel², S. Pallikkuth³, S. Pahwa³, A. Fernandez⁴, S. Anjan¹, G. Guerra⁵, M. Alcaide¹, Y. Natori¹
¹Division of Infectious Disease, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, ²University of Miami Miller School of Medicine, Miami, FL, ³Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL, ⁴Infectious Disease Associates of Tampa Bay, Tampa Bay, FL, ⁵University of Miami Jackson Memorial Hospital, Miami, FL
*Purpose: The purpose of this study was to evaluate long term humoral and cellular immunity generated following SARS-CoV-2 infection in solid organ transplant recipients (SOTR).*Methods:…
2022 American Transplant Congress
Randomized, Phase 4 Study Evaluating the Pharmacokinetics and Tolerability of the New Tacrolimus Tablet Formulation (Tacrobell Tab) in Kidney Transplant Recipients
A. Han¹, E. Cho¹, H. Y. Woo¹, C. Ara¹, H. Lee², Y. Kim³, Y. Park⁴, J. Oh⁴, S. Min¹, J. Ha¹
¹Department of Surgery, Seoul National University College of Medicine, Seoul, Korea, Republic of, ²Seoul National University Hospital, Seoul, Korea, Republic of, ³Department of Nephrology, Seoul National University College of Medicine, Seoul, Korea, Republic of, ⁴Department of Clnical Pharmacology, Seoul National University Hospital, Seoul, Korea, Republic of
*Purpose: Previous twice-a-day tacrolimus formulations available were capsular and of limited dose formulations (0.5mg, 1mg). Recently a new tablet formulation of tacrolimus with more diverse…
2022 American Transplant Congress
COVID-19 Syndrome After Liver Transplant: Immunosuppression Role and Risk Factors for Mortality
M. M. Pascale¹, F. Frongillo¹, G. Bianco¹, F. Galiandro², E. Nure¹, S. Agnes¹, F. Giovinazzo¹
¹General Surgery and Liver Transplant Unit, Fondazione IRCSS - Policlinico "A. Gemelli", Roma, Italy, ²General Surgery Unit, ULSS3 Serenissima, Venezia, Italy
*Purpose: Data on mortality and immunosuppression role regarding Liver transplant recipients affected by COVID-19 are still under debate. The present study identified risk factors for…
2022 American Transplant Congress
Disruption of B Cell Population is Associated with Increased Infections in Pediatric Transplant Recipients
B. Geng, L. Loop, C. Anterasian, D. Mortazavi, J. Kitsen, C. Collins, K. Newton, E. Ingulli
Pediatrics, UCSD Rady Children's, San Diego, CA
*Purpose: Solid-organ transplant recipients are placed on long-term immunosuppression, preventing graft rejection but increasing the risk of infection. Pediatric transplant recipients are at increased risk…
2022 American Transplant Congress
Accepting Rejection in Liver Transplant Recipients Requiring Renal Replacement Therapy: A Practice Paradigm
S. Farghaly¹, T. Sparkes¹, B. Masters¹, A. Haririan², N. Jakhete³, R. N. Barth⁴, D. Maluf⁵, S. Freedman¹
¹Pharmacy, University of Maryland Medical Center, Baltimore, MD, ²Nephrology, University of Maryland Medical Center, Baltimore, MD, ³Hepatology, University of Maryland Medical Center, Baltimore, MD, ⁴Transplant Surgery, University of Chicago Medical Center, Chicago, IL, ⁵Transplant Surgery, University of Maryland Medical Center, Baltimore, MD
*Purpose: The purpose of this study is to evaluate rejection outcomes in those requiring renal replacement therapy (RRT) after liver transplant.*Methods: This was a single…